📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 17:59
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
97.8% Profit Drop: Bafna Pharma Q1 Net Profit Falls to ₹7.51 Lakhs; Revenue Down 23%
Bafna Pharmaceuticals reported a significant downturn in its Q1 FY27 results, with revenue from operations declining 23.2% YoY to ₹26.58 crore. Net profit saw a near-total erosion, plummeting 97.8% to just ₹7.51 lakhs from ₹3.39 crore in the same period last year. The company's profitability was severely impacted by high material and manufacturing costs, which consumed nearly all of its total income. Additionally, the company is contesting GST-related demands and refund recoveries totaling ₹5.66 crore, a figure representing over 50% of its entire FY26 net profit.
Confidence: HIGH
What changedThe company experienced a sharp YoY contraction in both top-line revenue and bottom-line profitability for the quarter ended June 2026.
Why it mattersThe near-zero quarterly profit and high legal contingencies relative to annual earnings indicate significant operational and regulatory stress for the small-cap pharmaceutical player.
Q1 Revenue: ₹26.58 crQ1 Net Profit: ₹0.075 crYoY Revenue Change: -23.2%YoY Net Profit Change: -97.8%GST Dispute vs FY26 PAT: ~51%
📅 Short termThe stock is likely to face negative pressure in the short term due to the substantial earnings miss and the high expense-to-income ratio.
📈 Long termLong-term recovery depends on the successful execution of the planned ₹24.5 crore capex and reducing high customer concentration (top 3 clients contribute 73% of sales).
⚠ Risk flags
- Severe margin erosion
- High customer concentration
- Significant GST litigation (₹5.66 cr)
- Revenue contraction
Key Highlights
Revenue from operations fell to ₹26.58 crore in Q1 FY27 from ₹34.62 crore in Q1 FY26.
Net profit for the quarter collapsed to ₹7.51 lakhs, down from ₹3.39 crore in the previous year's quarter.
Total expenses of ₹28.42 crore were nearly equal to the total income of ₹28.49 crore, leading to razor-thin margins.
The company faces a GST demand of ₹2.35 crore and a refund recovery order of ₹3.31 crore, both currently under legal challenge.
Earnings Per Share (EPS) dropped to ₹0.03 from ₹1.43 in the year-ago period.
👀 What to Watch
Investors should monitor the company's ability to stabilize its operating margins and recover revenue growth in the coming quarters. The outcome of the GST litigation in the Madras High Court is a critical factor to watch, given the potential impact of the ₹5.66 crore dispute on the company's limited cash flows.
Bafna Pharma Q1 Net Profit Drops 97% YoY to ₹7.51 Lakhs; Revenue Down 23%
Bafna Pharmaceuticals reported a weak Q1 FY27, with revenue from operations declining 23.2% YoY to ₹26.58 Cr. Net profit saw a severe contraction, falling to ₹7.51 Lakhs from ₹3.39 Cr in the same period last year, as total expenses of ₹28.42 Cr nearly offset total income. The company is currently contesting GST demands and refund recoveries totaling ₹5.66 Cr, which represents approximately 10.6% of its TTM revenue. The Board has scheduled the 31st Annual General Meeting for September 11, 2026.
Confidence: HIGH
What changedThe company has moved from a profitable position in the previous quarter (₹2.75 Cr) to a near-break-even result (₹7.51 Lakhs) in Q1 FY27, alongside a significant YoY revenue drop.
Why it mattersThe sharp decline in margins and revenue, combined with legal disputes totaling over 10% of TTM revenue, highlights operational volatility and regulatory risks for a company with high customer concentration.
Revenue (Q1 FY27): ₹26.58 CrNet Profit (Q1 FY27): ₹7.51 LakhsYoY Revenue Growth: -23.2%Total GST Dispute Value: ₹5.66 CrDispute vs TTM Revenue: ~10.6%
📅 Short termThe stock may face downward pressure due to the significant earnings miss and the auditor's emphasis on matter regarding the GST disputes.
📈 Long termLong-term recovery depends on diversifying the client base (currently 73% from top 3 customers) and successfully scaling the lifestyle disease segment through planned capex.
⚠ Risk flags
- Sharp margin erosion
- High customer concentration (73% of sales)
- Significant tax litigation (₹5.66 Cr)
- High product concentration (top 3 products = 51.5% of revenue)
Key Highlights
Revenue from operations fell to ₹26.58 Cr in Q1 FY27 from ₹34.62 Cr in Q1 FY26.
Net profit plummeted by 97.8% YoY to ₹7.51 Lakhs compared to ₹3.39 Cr in the previous year's quarter.
Total expenses for the quarter stood at ₹28.42 Cr, resulting in a thin profit before tax of ₹7.51 Lakhs.
Contingent liabilities include a GST demand of ₹2.35 Cr and a refund recovery order of ₹3.31 Cr.
The 31st AGM is scheduled for September 11, 2026, with a book closure starting September 05, 2026.
👀 What to Watch
Investors should monitor the progress of the GST litigation in the Madras High Court and track the execution of the previously announced ₹24.5 Cr capex plan to see if it can reverse the current revenue decline.
Bafna Pharma FY26 Net Profit Jumps 167% to ₹11.10 Cr; Annual Revenue Reaches ₹150.6 Cr
Bafna Pharmaceuticals reported a robust performance for the full year ended March 31, 2026, with net profit surging to ₹1,109.98 lakhs from ₹415.25 lakhs in the previous year. While Q4 FY26 revenue saw a marginal YoY dip to ₹3,828.58 lakhs, the total annual revenue grew to ₹15,061.74 lakhs. The company's EPS improved significantly to ₹4.69 from ₹1.76. However, investors should monitor ongoing GST litigation involving demands and refund recoveries totaling approximately ₹566 lakhs.
Key Highlights
Annual Net Profit surged by 167% YoY to ₹1,109.98 lakhs in FY26.
Full-year Revenue from Operations increased to ₹15,061.74 lakhs compared to ₹14,585.70 lakhs in FY25.
Earnings Per Share (EPS) rose substantially to ₹4.69 from ₹1.76 in the previous fiscal year.
Property, Plant and Equipment (PPE) increased to ₹8,179.02 lakhs from ₹5,877.99 lakhs, indicating significant capital expenditure.
The company is contesting GST demands and refund recoveries totaling ₹566.56 lakhs, currently under appeal/stay.
👀 What to Watch
Investors should view the strong bottom-line growth and asset expansion positively, but remain cautious regarding the potential impact of the GST legal disputes highlighted by the auditors.
Bafna Pharma Q3 FY26 Net Profit Rises 94% YoY to ₹1.84 Cr; Revenue Up 15%
Bafna Pharmaceuticals reported a steady year-on-year performance for Q3 FY26, with revenue from operations growing 15.4% to ₹38.29 crore. Net profit nearly doubled YoY to ₹1.84 crore, although it saw a sequential decline from ₹3.12 crore in Q2 FY26. The company is currently navigating significant regulatory hurdles, including GST demands totaling approximately ₹5.66 crore and overdue foreign currency receivables of ₹2.05 crore. Despite these challenges, the nine-month profit before tax has improved significantly to ₹5.31 crore from ₹2.84 crore in the previous year.
Key Highlights
Revenue from operations grew 15.4% YoY to ₹38.29 crore in Q3 FY26.
Net Profit for the quarter stood at ₹1.84 crore, up 93.8% from ₹0.95 crore in Q3 FY25.
Nine-month Profit Before Tax (PBT) surged to ₹5.31 crore compared to ₹2.84 crore in the prior year period.
Contingent liabilities include GST demands of ₹235.47 lakhs and ₹331.09 lakhs currently under appeal.
Foreign currency receivables of ₹2.05 crore are outstanding beyond RBI-stipulated timelines, requiring extension approvals.
👀 What to Watch
Investors should monitor the outcome of the GST appeals as the total demand of over ₹5.6 crore is substantial compared to annual profits. While operational growth is positive, the sequential margin compression and regulatory 'Emphasis of Matter' by auditors warrant a cautious approach.
Bafna Pharma Credit Outlook Upgraded to Positive by ICRA; Reaffirms BB+ Rating
ICRA Limited has revised the credit outlook for Bafna Pharmaceuticals Limited from 'Stable' to 'Positive' while reaffirming its long-term rating at [ICRA] BB+. The rating applies to bank loan facilities totaling ₹50.00 crores, which include term loans of ₹25.87 crores and cash credit of ₹20.00 crores. Additionally, the short-term rating for non-fund-based facilities has been reaffirmed at [ICRA] A4+. This positive outlook indicates an expectation of improved financial stability and debt-servicing capability in the future.
Key Highlights
Outlook revised from 'Stable' to 'Positive' for ₹50.00 crore total bank facilities.
Long-term rating reaffirmed at [ICRA] BB+ for ₹25.87 crore term loans and ₹20.00 crore cash credit.
Short-term rating for Letter of Credit facilities reaffirmed at [ICRA] A4+.
The revision reflects ICRA's assessment of an improving credit profile for the pharmaceutical firm.
👀 What to Watch
The outlook upgrade is a positive signal regarding the company's creditworthiness and could lead to lower interest expenses. Investors should monitor if this leads to a formal rating upgrade in the next 12 months.
